New anxiety pill shows promise in major trial
NCT ID NCT06809595
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This study tests an oral medication called MM120 against a placebo in 245 adults with generalized anxiety disorder. Participants take the drug or placebo for 12 weeks, and those who complete may join a 40-week follow-up where everyone gets the active drug. The goal is to see if MM120 reduces anxiety symptoms more than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
4 Medical Clinical Solutions
London, United Kingdom
-
4 Medical Clinical Solutions
Manchester, United Kingdom
-
A-shine s.r.o.
Pilsen, Czechia
-
Adams Clinical Boston
Boston, Massachusetts, 02116, United States
-
Atlanta Center for Medical Research
Atlanta, Georgia, 30331, United States
-
Austin Clinical Trial Partners
Austin, Texas, 78737, United States
-
Bradenton Research Center, Inc.
Bradenton, Florida, 34205, United States
-
CMME
Paris, France
-
Cabinet Dr.Desbonnet : Résidence Saint Michel
Douai, France
-
Central Institute of Mental Health
Mannheim, Germany
-
Centre Hospitalier du Rouvray
Sotteville-lès-Rouen, France
-
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Poland
-
Clerkenwell Health
London, United Kingdom
-
Clerkenwell Health - Baker Street
London, United Kingdom
-
Clinical Neuroscience Solutions, Inc
Orlando, Florida, 32801, United States
-
Core Clinical Research
Everett, Washington, 98201, United States
-
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, St. Nicholas Hospital
Gosforth, United Kingdom
-
Department of Affective and Psychotic Disorders, Central Teaching Hospital, Medical University of Lodz
Lodz, Poland
-
Department of Psychiatry and Psychotherapy Campus Charité Mitte Charité Universitätsmedizin Berlin
Berlin, Germany
-
Department of Psychiatry, UCK
Gdansk, Poland
-
GHU Paris Psychiatrie et Neurosciences
Paris, France
-
Hôpital Conception, CIC Centre, bat néphrologie 3eme étage
Marseille, France
-
Institut Neuropsychiatricke Pece (INEP)
Prague, Czechia
-
Klinik für Psychiatrie und Psychotherapie, Abt: Allgemeine Psychiatrie und Psychotherapie
Tübingen, Germany
-
Neuro-Behavioral Clinical Research, Inc.
North Canton, Ohio, 44720, United States
-
Neuroclin Glasgow
Glasgow, United Kingdom
-
OVID Clinic Berlin
Berlin, Germany
-
Preferred Research Partners, Inc.
Little Rock, Arkansas, 72211, United States
-
Princeton Medical Institute
Princeton, New Jersey, 08540, United States
-
Psychedelic Science Institute
Los Angeles, California, 90004, United States
-
Psyon s.r.o.
Prague, Czechia
-
Sheppard Pratt Health System
Towson, Maryland, 21204, United States
-
South London and Maudsley NHS Foundation Trust of The Maudsley Hospital
London, United Kingdom
-
St George's Community Health Centre
Sheffield, United Kingdom
-
University of Cincinnati Psychiatry- Anxiety Disorders Research Program
Cincinnati, Ohio, 45219, United States
-
West Los Angeles VA Medical Center
Los Angeles, California, 90073, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill quiet the mind? a large trial puts it to the test
- Can a unified therapy tame both addiction and emotional disorders?
- Can learning Self-Compassion quiet anxiety and depression?
- A common antidepressant may tame anxiety in kids with autism and ADHD — a trial puts it to the test
- Can money worries trigger depression in students? a study digs deep
- Could a group therapy tackle both depression and anxiety in teens?